Key

Inclusion Criteria:

- Demonstrated a response (CR, CRu, or PR) on Study 114-NH-301 (Galiximab in
combination with Rituximab compared with Rituximab in combination with Placebo) and
then relapsed or progressed with a TTP >=6 months. Relapsed disease is defined as
documented disease progression using the International Workshop Response Criteria
(IWRC).

- Bidimensionally measurable disease with at least 1 lesion >=2.0 cm in a single
dimension.

- Acceptable hematologic, hepatic, and renal function.

Key Exclusion Criteria:

- Any lymphoma therapy between Final Visit on Study 114-NH-301 and Study Day 1 of this
retreatment study.

- Chronic or intermittent corticosteroids for inflammatory or autoimmune disorders
within 3 weeks prior to Study Day 1.

- Transfusion-dependent subjects.

- Presence of central nervous system (CNS) lymphoma.

- Histologic transformation.

- Presence of pleural or peritoneal effusion with positive cytology for lymphoma.

- Another primary malignancy requiring active treatment.

- Serious nonmalignant disease (e.g., congestive heart failure, hydronephrosis); active
uncontrolled bacterial, viral, or fungal infections; or other conditions that would
compromise protocol objectives in the opinion of the Investigator and/or the Sponsor.

- New York Heart Association Class III or IV cardiac disease or myocardial infarction
within 6 months prior to Study Day 1.